Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo [1] Group 1: Strategic Partnership - Heptagon Pharmaceuticals and Evinova announced a strategic cooperation to leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development [1] - The partnership aims to build an AI-driven open ecosystem for drug research and development by utilizing each company's strengths [1] Group 2: AI Platform Development - Heptagon Pharmaceuticals launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ AI platform during a global R&D day event in Shanghai [1] - The model is based on proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, the platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1]
港股异动 | 和铂医药-B(02142)涨超5% 与Evinova达成战略合作 构建AI驱动药物研发开放式生态系统